William Blair analyst Max Smock has reiterated their bullish stance on ICLR stock, giving a Buy rating on October 20.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Max Smock has given his Buy rating due to a combination of factors influencing Icon’s performance. Despite a mixed third-quarter report, where revenue exceeded expectations but margins were softer than anticipated, the company still managed to raise its 2025 revenue outlook. This indicates potential for growth, even though adjusted EBITDA and EPS fell short of estimates, partly due to a challenging pricing environment affecting margins.
Moreover, Icon’s ability to maintain a book-to-bill ratio above 1.00x, despite elevated cancellations, reflects its resilience. The company also demonstrated financial strength by repurchasing $250 million worth of stock, leveraging its strong balance sheet. While demand commentary remains cautious, with ongoing pressures in clinical development and macroeconomic factors, the positive momentum in RFP flow and biotech funding provides a promising outlook, justifying the Buy rating.
Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ICLR in relation to earlier this year.